Pharmacokinetics of levetiracetam

Epilepsia

Volumn 42, Issue SUPPL. 4, 2001, Pages 24-27

  Radtke, R A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Levetiracetam; Pharmacokinetics

Indexed keywords

ETIRACETAM;

AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; EPILEPSY; FOCAL EPILEPSY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0034864245     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2001.00005.x     Document Type: Review

References (6)

1. Selection of anti-epileptic drug therapy
2. Physicians' desk reference. 55th ed.
3. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
4. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique
5. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers